Study of belumosudil for cGVHD in diverse patients withdrawn
Disease control
Terminated
This study aimed to test the safety and effectiveness of the oral drug belumosudil in Black, Native American, and Pacific Islander patients aged 12 and older with chronic graft-versus-host disease (cGVHD) who had already tried at least two other treatments. The goal was to see if…
Phase: PHASE2 • Sponsor: Kadmon, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC